My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking

Sun Pharmaceuticals Industries Ltd Research Report - 17th Aug 2016

Pharmaceutical | Published on Aug 17th 2016

IT

The company’s sales for 1QFY2017 came in higher than expected at Rs8,007cr V/s Rs7,414cr expected and V/s Rs6,526cr in 1QFY2016, a yoy growth of 22.7%, mainly driven by exports. On the operating front, the EBITDA margin came in at 33.5% V/s 29.5% expected and V/s 23.5% in 1QFY2016, mainly driven by gross margin expansion (76.9% in 1QFY2017 V/s 74.1% in 1QFY2016). Thus, the Adj. net profit came in at Rs2,034cr V/s Rs1,602cr expected and V/s Rs1,070cr in 1QFY2016. We maintain our Buy rating. Results outperform: Company’s sales for 1QFY2017 came in higher than expected at Rs8,007cr V/s Rs7,414cr expected and V/s Rs6,526cr in 1QFY2016, a yoy growth of 22.7%, mainly driven by exports. Export formulations (Rs5,664cr) grew 25.6% yoy, while Indian formulations (Rs1,854cr) grew 7.6% yoy. API sales (Rs470cr) grew 73.1% yoy. On the operating front, the EBITDA margin came in at 33.5% V/s 29.5% expected and V/s 23.5% in 1QFY2016, mainly driven by gross margin expansion (76.9% in 1QFY2017 V/s 74.1% in 1QFY2016). R&D expenditure during the quarter was 9.1% of sales V/s 5.5% of sales in 1QFY2016. Thus, the Adj. net profit came in at Rs2,034cr V/s Rs1,602cr expected and V/s Rs1,070cr in 1QFY2016. Outlook and valuation: Sun Pharma is one of the largest and fastest growing Indian pharmaceutical companies. We expect its net sales to post a 12.7% CAGR (including Ranbaxy Laboratories) to Rs35,258cr and EPS to post a 22.0% CAGR to Rs32.8 over FY2016–18E. We recommend a Buy on the stock.

Download Full Report

Sell

CMP 783
Target Price 944
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)Array
MCAP NSE (Rs in Cr)Array
P/E (x)Array
EPS (Rs.)Array
BV (Rs.)Array
Div Yield (%)Array
FV (Rs.)Array
P/BV (x)Array
EV/Sales (x)Array
EV/EBITDA (x)Array

Shareholding Pattern (%)

Promoter54.0
Foreign22.0
Institution12.0
Public & Others8.0
Corporate4.0
Grand Total100.0

Trade Securely

AngelEye

Portfolio Tracking & Trading Application View Demo